NCT00915460View on ClinicalTrials.gov

Open-Label Safety Extension Study of Avonex

PHASE4CompletedINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

June 30, 2003

Study Completion Date

July 31, 2003

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon beta-1a (Avonex)

dosage and frequency as per Biogen Idec protocol

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00915460 - Open-Label Safety Extension Study of Avonex | Biotech Hunter | Biotech Hunter